Earnings Preview: What To Expect From FedEx
FedEx is scheduled to report earnings after Thursday's close. The stock hit a record high of $319.90/share in 2021 and is currently trading near $246. The stock is prone to big moves after reporting earnings and can easily gap up if the numbers are strong. Conversely, if the numbers disappoint, the stock can easily gap down. To help you prepare, here is what the Street is expecting:
The company is expected to report a gain of $4.65/share on $21.89 billion in revenue. Meanwhile, the so-called Whisper number is a gain of $4.71/share. The Whisper number is the Street's unofficial view on earnings.
Click on the chart to join MarketSurge
The company has seen up and down earnings over the last few years. In 2020, the company made $9.50/share. In 2021, earnings vaulted to $18.17. Then, earnings grew to $20.61 in 2022. Earnings slid to $14.96 in 2023 and $17.80 in 2024. In 2025, earnings are expected to come in at $18.93 and $21.90 in 2026. The stock sports a price to earnings (P/E) ratio of 15 which is lower than the benchmark S&P 500.
Technically, the stock is in a long downtrend and not acting very well. The stock is trading below its 50-day moving average line (DMA) and below its longer-term 200-day moving average line which are both not healthy signs.
FedEx, originally known as Federal Express, was founded in 1971 by Frederick W. Smith in Little Rock, Arkansas. Smith, a Yale graduate, conceived the idea for an overnight delivery service in a term paper, which he later turned into a successful business. He raised $91 million in venture capital to support his vision. On April 17, 1973, Federal Express began operations in Memphis, Tennessee, with 389 team members. Memphis was chosen for its central U.S. location and favorable weather conditions. The company's first night saw 14 aircraft deliver 186 packages to 25 U.S. cities.
Throughout the 1980s and 1990s, FedEx expanded rapidly. By 1983, it became the first U.S. company to reach $1 billion in revenue within a decade of founding without mergers or acquisitions. FedEx expanded internationally in 1984, reaching Europe and Asia, and acquired Flying Tiger Line in 1988, becoming the largest full-service cargo airline. In 1994, Federal Express officially shortened its name to "FedEx" for marketing purposes, reflecting its broader service offerings. FedEx continued to innovate, earning the Malcolm Baldrige National Quality Award in 1990 as the first service company to do so.
By recent years, FedEx had grown into an approximately $87.7 billion global enterprise, serving over 220 countries and territories. Its operations include around 698 aircraft, over 200,000 vehicles, and roughly 5,000 facilities, with more than 500,000 employees handling about 15 million shipments daily. FedEx continues to innovate, unveiling a state-of-the-art automated sorting facility at the Memphis World Hub in October 2024. This facility enhances operational efficiency and speeds up delivery times. FedEx also focuses on sustainability and customer experience through its 2025 Plan, aiming to reduce its environmental impact while maintaining operational excellence.
FedEx Corporation, together with its subsidiaries, provides transportation, e-commerce, and business services in the United States and internationally. It operates through FedEx Express, FedEx Ground, FedEx Freight, and FedEx Services segments.
The FedEx Express segment offers express transportation, small-package ground delivery, and freight transportation services; and time-critical transportation services. The FedEx Ground segment provides small-package ground delivery services. The FedEx Freight segment offers less-than-truckload freight transportation services. The FedEx Services segment provides sales, marketing, information technology, communications, customer service, technical support, billing and collection, and back-office support services.
In addition, the company offers supply chain management solutions; and air and ocean freight forwarding and cargo transportation, specialty transportation, customs brokerage, third party logistics and supply chain, and document and business solutions, as well as provides trade management tools and data.
From where I sit, the most important trait I look for during earnings season is how the market and a specific company reacts to the news. Remember, always keep your losses small and never argue with the tape.
Disclosure: The stock has been featured on FindLeadingStocks.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
an hour ago
- CNBC
Earnings playbook: Disney and Advanced Micro Devices lead another busy week of reports
The busiest week of earnings has passed, but there are still dozens of key reports still to come that could shake up Wall Street. About 120 S & P 500 companies are scheduled to post their latest earnings. Among them are Disney , Advanced Micro Devices and Dow Jones Industrial Average member Pfizer . Those come after investors last week got quarterly reports from megacap names including Microsoft , Apple , Amazon and Meta Platforms . Roughly two-thirds of the companies in the S & P 500 index have posted quarterly results, with more than 82% exceeding earnings expectations, according to FactSet. Take a look at CNBC Pro's breakdown of what to expect in this week's key reports. All times are ET. Tuesday Pfizer is set to report earnings before the bell. A call is scheduled for 10 a.m. Last quarter: PFE topped expectations as it expanded cost-cutting efforts . This quarter: Analysts expect the pharmaceutical giant to report a slight year-over-year earnings decline, according to LSEG. What to watch: Investors will look for guidance around President Donald Trump's push to lower drug prices — and how that could affect Pfizer's future earnings. The earnings call will likely focus on "RFK Jr and possible risks to vaccines; [and] obesity franchise aspirations and/or other early pipeline opportunities like PFE's next-gen PCV vaccines," BofA analyst Tim Anderson said last month, referring to the Secretary of Health and Human Services. What history shows: Pfizer has a strong track record of exceeding earnings estimates, with the company's bottom line beating expectations 87% of the time, according to Bespoke Investment Group. AMD is set to report earnings after the close, followed by a conference call at 5 p.m. Last quarter: AMD beat on earnings but said it would take a $1.5 billion revenue hit due to restrictions on sales of chips to China. This quarter: Analysts polled by LSEG expect a mixed quarter, with earnings forecast to have dropped nearly 30% year over year, while revenue is anticipated to have grown more than 25%. What to watch: "We see an upside bias for FQ2 (June) results driven by both PC and server" demand, wrote UBS analyst Tim Arcuri on July 28, who rates AMD a buy. "Investors should, however, not expect any quantitative data center GPU commentary for next year as it is probably still too early for AMD to talk about next year other than to say that it feels very good about growth," he added, referring to graphics processing units. What history shows: AMD has fallen after two of the last three earnings releases, including a 6.3% slide after Q4 results came out and an 11% slump following mixed Q3 figures. Super Micro Computer is set to report earnings postmarket. Management's conference call with analysts and institutional investors is slated for 5 p.m. Last quarter: SMCI issued weak guidance, citing " economic uncertainty and tariff impacts ." This quarter: The data center company is expected to post a steep, year-over-year decline in earnings, LSEG data shows. What to watch: JPMorgan analyst Samik Chatterjee placed SMCI on "negative catalyst watch" ahead of these forthcoming earnings, noting "upside in relation to AI demand drivers is likely to be offset by margin pressures stemming from an increasingly competitive landscape, driving downside to the premium valuation multiple SMCI shares are currently trading at." What history shows: According to Bespoke, Super Micro only beats earnings estimates 64% of the time. However, the stock averages a 2.3% advance when the company reports its latest financials. Wednesday Disney is set to report earnings before the bell, followed by a call at 8:30 a.m. Last quarter: DIS climbed on a surprise uptick in streaming subscribers . This quarter: Analysts anticipate the theme park and media giant will report year-over-year earnings growth of about 7%, per LSEG. What to watch: Disney shares have struggled recently, losing more than 5% in the past month, while the S & P 500 is up slightly. Can this report put the House of Mouse back on track? What history shows: Disney earnings have topped earnings expectations in seven of the last eight quarters, per Bespoke. Thursday Eli Lilly is set to report earnings premarket, with a call slated for 8:30 a.m. Last quarter: LLY posted a 45% sales surge on strong demand for weight loss drugs. This quarter: Analysts polled by LSEG expect the Indianapolis-based drugmaker to reveal earnings growth of around 40%. What to watch: Investors will look for continued momentum out of Eli Lilly's Mounjaro weight loss drug. Last week, Lilly said Mounjaro has shown similar heart health benefits in a head-to-head trial with diabetes drug Trulicity, also made by Lilly. What history shows: Bespoke data shows Lilly beats Wall Street expectations 66% of the time. However, the stock doesn't perform well on earnings days, averaging a 0.2% decline.
Yahoo
2 hours ago
- Yahoo
Palantir, AMD, Disney: Earnings to watch this week
Asking for a Trend host Josh Lipton goes over the biggest earnings reports to keep an eye on during the week of Monday, Aug. 4. Palantir (PLTR) will report its second quarter results after markets close on Monday. Investors expect good results from the company's commercial segment. Advanced Micro Devices (AMD) will release its second quarter results after markets close on Tuesday. Investors will be looking at GPU sales, artificial intelligence (AI) revenue, and plans for further growth in the second half of the year. Disney (DIS) will post its results before markets open on Wednesday. Investors anticipate a solid report likely unaffected by competitors and will be looking for updates on the company's growth in the streaming space. To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend. Well, time now for to watch and earnings coming up. Palantir, AMD, and Disney. Start with Palantir, which is reporting second quarter earnings after the bell on Monday. Company stock has shot up over 100% year to date marking the company as one of the best performing stocks in the S&P 500. Investors expecting good results for Palantir's commercial segment. They're aware of pressures like potential competition and defense contracts and other AI giants. And next up, we got AMD. It's set to release its second quarter results after the bell Tuesday. The semiconductor manufacturers stock has rallied massively throughout the quarter spurred on by the booming AI trade as well as momentum in the company's PC business. As a result, investors expecting solid future results with more emphasis in GPU sales, AI revenue, and preparations to grow the company in the second half of 2025. And finally, talk about Disney, which reports earnings before the bell on Wednesday. Analysts saying that the media giant will have a solid third quarter likely unaffected by competitors attempting to break into the theme park space like Comcast's Epic Univers Universe. Investors watching for updates on the media giant's growth in the streaming arena. Related Videos Bad news flurry, IPO market, crypto dive: Market takeaways Earnings, Fed commentary, consumer credit: What to Watch IPO market heats up: These 4 names prepare to go public next Berkshire Hathaway earnings: 'Perfect' stock to own when 'worried' Effettua l'accesso per consultare il tuo portafoglio
Yahoo
3 hours ago
- Yahoo
Oppenheimer Predicts Up to 590% Rally for These 2 ‘Strong Buy' Stocks
There's a lot to say about the economy and markets today. Earnings season is well underway, with 317 S&P 500 companies having reported so far, and the results have been broadly encouraging – 83% have topped profit forecasts. That strength has helped drive both the S&P 500 and NASDAQ toward record highs, although August began with a pullback as investors reacted to a weaker-than-expected jobs report and the rollout of new tariffs from President Trump. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Even with those headwinds, Oppenheimer's chief investment strategist John Stoltzfus remains optimistic about the path ahead. 'This year reminds us of the classic Charles Dickens quote, 'It was the best of times, it was the worst of times.' Although much uncertainty and worry prevailed for some time both with trade policy and geopolitical events, and given the multitude of potential outcomes, we'd note that cooler heads prevailed – leading to positive outcomes at least for now. Monetary policy by the Fed has brought down the pace of inflation (if not yet to its 2% target level) without thus far causing a recession. This in our view is a substantial achievement… We are revising our year-end price target for the S&P 500 to 7,100 from 5,950,' Stoltzfus noted. That S&P target implies a gain of ~14% from current levels, a solid gain by any standard. But some stocks are going to outperform, even substantially – and Oppenheimer analysts are predicting much stronger rallies for 2 names in particular, including one with a potential upside as high as 590%. Using the TipRanks database, we've looked at the big-picture view on both of these picks, and it seems the broader Street agrees with Oppenheimer's bullish stance – both stocks hold Strong Buy consensus ratings, with forecasts pointing to potential triple-digit gains. Let's dig into what makes these high-upside picks so compelling. Climb Bio (CLYM) We'll start with Climb Bio, a biotech research firm focused on developing new treatments for immune-mediated diseases. These conditions – affecting an estimated 1 in 7 people worldwide – often stem from malfunctioning B cells, which can mistakenly attack the body's own tissues. Climb is developing therapies that target this root cause, aiming to address a range of serious and underserved diseases. The company's pipeline includes two drug candidates: its lead program, budoprutug, is currently being tested in three clinical trials and one preclinical study, while its second candidate, CLYM116, remains in preclinical development. Budoprutug is an anti-CD19 monoclonal antibody designed to deplete B cells. The drug has shown encouraging early clinical data and is now being evaluated in clinical trials across three distinct indications: primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). In pMN, a rare autoimmune kidney disorder that causes damaging protein leakage into the urine, budoprutug is entering a Phase 2 open-label, dose-ranging trial to assess safety and efficacy. This follows positive data from a small Phase 1b study, in which 3 of 5 patients who completed all four doses achieved complete remission of proteinuria. All five patients in that study experienced rapid and sustained B-cell depletion, even at the lowest tested dose of 100 mg, and no serious drug-related adverse events were reported. Meanwhile, in ITP, Climb has received FDA clearance to begin a Phase 1b/2a study, with the trial now advancing. ITP is an autoimmune disorder in which B cells produce antibodies that target and destroy platelets. Budoprutug is being tested in this setting based on its CD19-targeting mechanism, which may offer an advantage over CD20-based therapies by depleting a broader range of B-cell populations, including plasma cells that drive the underlying disease process. The drug is also being explored in SLE, a chronic autoimmune disease that can cause widespread inflammation and tissue damage across multiple organs. A Phase 1b trial has been cleared by the FDA and is set to run at ex-U.S. sites. This open-label study is designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and early signs of clinical efficacy. Climb's B-cell-targeted approach is supported by the well-established role these cells play in driving lupus pathogenesis. To further expand its reach, Climb is also developing a subcutaneous formulation of budoprutug, with a Phase 1 trial in healthy volunteers expected to begin by year-end. Beyond budoprutug, Climb is advancing its second candidate, CLYM116, an Fc-engineered anti-APRIL monoclonal antibody with a novel pH-dependent mechanism. Currently in preclinical development, CLYM116 is being explored as a treatment for IgA nephropathy (IgAN), a serious kidney disorder also known as Berger's disease. Climb expects to report preclinical data and submit an Investigational New Drug (IND) application or Clinical Trial Application (CTA) by year-end. With CLYM trading at $1.45, Oppenheimer analyst Leland Gershell views the stock as a high-potential opportunity, pointing to the company's advancing clinical pipeline and the therapeutic promise of budoprutug. 'We have a favorable outlook on budoprutug across its three indications in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE)… Each of these indications has clear IgG-driven pathophysiology and significant residual unmet need, despite existing first- and second-line therapies, where budoprutug has opportunity to shine above… We see $1B+ sales potential across these indications, and a subcutaneous, potentially use-at-home version offers upside optionality… With shares reflecting little credit for the company's opportunities and cash runway into 2027, we see favorable risk-reward and encourage investors to build a position. We would expect positive results in pMN to generate considerable stock upside potential,' Gershell opined. So how much upside does Gershell see overall? The analyst rates CLYM an Outperform (i.e., Buy), with a $10 price target – implying a substantial 590% surge over the next year. (To watch Gershell's track record, click here) Supporting this optimistic outlook, CLYM has 3 recent analyst reviews on record – all unanimously positive – earning the stock a Strong Buy consensus rating. With an average price target of $9, analysts expect shares to be changing hands at ~521% premium over the next 12 months. (See CLYM stock forecast) Wave Life Sciences (WVE) The next Oppenheimer pick is Wave Life Sciences, a biotech company developing a lineup of RNA medicines through its proprietary platform, dubbed PRISM. RNA therapeutics represent a fast-growing frontier in biotechnology, and Wave is harnessing innovations in chemistry and human genetics to create targeted treatments for serious, genetically driven diseases that have historically lacked effective solutions. This ambitious vision is translating into a diverse clinical pipeline. Wave is advancing four distinct programs, each built on a separate RNA modality: WVE-006 uses RNA editing, WVE-007 employs RNA interference (RNAi), WVE-N531 leverages exon skipping, and WVE-003 utilizes allele-selective silencing. By tackling different mechanisms and indications, the company is positioning itself to address multiple areas of high unmet medical need. WVE-006 is a GalNAc-conjugated, subcutaneously delivered RNA editing oligonucleotide (AIMer) designed to treat alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting the lungs and liver. The drug is currently in the Phase 1b/2a RestorAATion-2 trial, with key clinical data from both the 200 mg single and multidose cohorts expected in the third quarter of 2025. Additional results from the 400 mg single-dose cohort are anticipated later this fall. Progress is also accelerating with WVE-007, an RNAi therapy targeting obesity. This GalNAc-siRNA candidate works by silencing the INHBE gene and has shown strong preclinical efficacy in reducing weight while preserving muscle mass. Following promising initial safety and pharmacodynamic results in Cohort 1, Wave expanded enrollment in Cohort 2 and expects data from the first two cohorts in Q4 2025, with high-dose cohort results to follow in early 2026. The third program, WVE-N531, is an exon-skipping oligonucleotide developed for Duchenne muscular dystrophy (DMD), a severe and progressive neuromuscular disorder. In a Phase 2 open-label trial, the therapy showed statistically significant and clinically meaningful improvements in Time-to-Rise, a key measure of functional strength. Wave plans to submit a New Drug Application (NDA) in 2026 to pursue accelerated approval. Rounding out the clinical pipeline is WVE-003, an allele-selective oligonucleotide designed for Huntington's disease (HD). This first-in-class candidate has demonstrated selective reduction of mutant huntingtin protein (mHTT) while preserving healthy wild-type HTT – an approach believed to protect neuronal function. A Phase 2/3 trial is in planning, with Wave aiming to submit an IND in the second half of 2025. This pipeline, and its potential for success, has caught the attention of Oppenheimer analyst Cheng Li, who writes: 'We think RNA medicine is poised to become an important therapeutic modality for future medicine, leveraging its unique target engagement mechanism compared to other modalities. The PRISM platform further enhances the potency, durability, tissue distribution, and pharmacological properties of oligonucleotides in a multimodal fashion… We are optimistic about WVE's four clinical programs, each having its own merits and collectively providing validation to the platform technology that propels a next wave of programs for high-value targets with differentiated approaches… We anticipate multiple meaningful clinical catalysts from WVE-006 for alpha1 antitrypsin deficiency (AATD) and WVE-007 for obesity, with current valuation offering a favorable risk/reward setup.' Reflecting this conviction, Li assigns WVE an Outperform (i.e., Buy) rating, along with a $24 price target that suggests shares could surge 178% over the next year. (To watch Li's track record, click here) Li's bullish stance is echoed across the Street. The stock has picked up 12 recent analyst reviews, supporting a Strong Buy consensus rating, with an 11-to-1 split favoring Buys over Holds. Shares currently trade at $8.63, and the average price target of $18.18 points to a potential upside of ~111% over the next 12 months. (See WVE stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
